What is Achieve Life Sciences?
Achieve Life Sciences is a specialty pharmaceutical company dedicated to combating the worldwide epidemic of smoking-related health issues and nicotine addiction. The company's core focus is on the development and commercialization of cytisinicline, a promising therapeutic agent aimed at aiding smoking cessation. The recent enterprise-level funding indicates a critical phase of scaling and market penetration for their lead candidate.
How much funding has Achieve Life Sciences raised?
Achieve Life Sciences has raised a total of $85M across 2 funding rounds:
Debt
$25M
Other Financing Round
$60M
Debt (2021): $25M with participation from Silicon Valley Bank
Other Financing Round (2024): $60M led by Nantahala Capital Management, Sopharma, and Propel Bio Partners
Key Investors in Achieve Life Sciences
Nantahala Capital Management
Nantahala Capital Management is an alternative investment firm specializing in micro-cap stocks, suggesting a focus on early to mid-stage companies with high growth potential.
Sopharma
Sopharma, a major pharmaceutical manufacturer in Bulgaria, brings significant industry expertise and potential for manufacturing and distribution synergies.
Propel Bio Partners
Propel Bio Partners focuses on advancing groundbreaking life science technologies and therapies, indicating a strategic interest in innovative healthcare solutions like those developed by Achieve Life Sciences.
What's next for Achieve Life Sciences?
With a major strategic investment and substantial total funding, Achieve Life Sciences is poised for significant expansion. The company is likely to accelerate its clinical trial programs, enhance its manufacturing capabilities, and prepare for the commercial launch of cytisinicline. This capital infusion will be instrumental in navigating regulatory pathways and establishing a strong market presence in the highly competitive smoking cessation sector. The strategic nature of the recent financing suggests a focus on partnerships and market access initiatives to maximize the impact of their therapeutic innovation.
See full Achieve Life Sciences company page
